Akson Pharmaceuticals (Pvt) Ltd
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Pharmaceutical manufacturer · Peshawar · Pakistan
Peshawar-based pharmaceutical manufacturer with manufacturing, import, export and branded-product operations.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Akson Pharmaceuticals
- Company type
- Pharmaceutical manufacturer
- Address
- Plot No. 66-A, Industrial Estate, Hayatabad, Peshawar, Khyber Pakhtunkhwa, Pakistan
- Website
- aksonpharma.com ↗
- Phone
- +92 91 2651455; +92 91 2652455
- info@aksonpharma.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Akson Pharmaceuticals (Pvt) Ltd is priced against the market
84 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Aksidrin | Ephedrine | 30 mg | Tablet | 1 x 1000’s | 068255 | PKR 483.64 | PKR 0.48/tablet | 🔒 Pharma Pro |
| Aksofen | Ibuprofen | 400 mg | Tablet | 25 x 10's | 023736 | PKR 879.35 | PKR 3.52/tablet | 🔒 Pharma Pro |
| Aksofen | Ibuprofen | 100 mg/5 mL | Suspension | 90 ml | 026938 | PKR 35.17 | PKR 0.39/mL | 🔒 Pharma Pro |
| Aksolox | Levofloxacin | 250 mg | Tablet | 1x10’s | 024607 | PKR 627.84 | PKR 62.78/tablet | 🔒 Pharma Pro |
| Aksolox | Levofloxacin | 500 mg | Tablet | 1x10’s | 024608 | PKR 1,237.21 | PKR 123.72/tablet | 🔒 Pharma Pro |
| Aksolox-750 | Levofloxacin | 750 mg | Tablet | 1 x 10’s | 073226 | PKR 923.29 | PKR 92.33/tablet | 🔒 Pharma Pro |
| Aksonem | Meropenem | 500 mg | Injection | 1's | 113975 | PKR 1,975.85 | PKR 1,975.85/vial/unit | 🔒 Pharma Pro |
| Aksonem | Meropenem | 1000 mg | Injection | 1's | 113976 | PKR 3,693.17 | PKR 3,693.17/vial/unit | 🔒 Pharma Pro |
| Aksopol | Paracetamol | 120 mg/5 mL | Suspension | 60 ml | 026940 | PKR 28.58 | PKR 0.48/mL | 🔒 Pharma Pro |
| Aksopol | Paracetamol | 500 mg | Tablet | 20 x 10's | 035276 | PKR 395.71 | PKR 1.98/tablet | 🔒 Pharma Pro |
| Aksovir | Hydroxychloroquine | 200 mg | Tablet | 50'S | 106264 | PKR 830.96 | PKR 16.62/tablet | 🔒 Pharma Pro |
| Aksovir | Hydroxychloroquine | 200 mg | Tablet | 30'S | 106264 | PKR 498.58 | PKR 16.62/tablet | 🔒 Pharma Pro |
| Aksoxime | Cefixime | 100 mg/5 mL | Suspension | 30ml | 029937 | PKR 314.24 | PKR 10.47/mL | 🔒 Pharma Pro |
| Aksoxime | Cefixime | 400 mg | Capsule | 5’s | 056274 | PKR 563.10 | PKR 112.62/capsule | 🔒 Pharma Pro |
| Aksoxime DS | Cefixime | 200 mg/5 mL | Suspension | 30ml | 056276 | PKR 384.56 | PKR 12.82/mL | 🔒 Pharma Pro |
| Akzith | Azithromycin | 250 mg | Capsule | 1x10’s | 068263 | PKR 470.88 | PKR 47.09/capsule | 🔒 Pharma Pro |
| Akzith 200mg/5ml SuspensionRegistry verified | Azithromycin | — | — | — | 136909Official source ↗ | No indexed price | — | — |
| Akzolid | Linezolid | 600 mg | Tablet | 12'S | 081652 | PKR 4,719.87 | PKR 393.32/tablet | 🔒 Pharma Pro |
| AkzolidInfusion | Linezolid | 200 mg/100 mL | IV infusion | 100ml | 081639 | PKR 638.92 | PKR 6.39/mL | 🔒 Pharma Pro |
| Amizin | Amikacin | 500 mg/2 mL | Injection | 2ml x 1’s | 037610 | PKR 230.82 | PKR 115.41/mL | 🔒 Pharma Pro |
| Amizin | Amikacin | 100 mg/2 mL | Injection | 2ml x 1’s | 037616 | PKR 75.71 | PKR 37.86/mL | 🔒 Pharma Pro |
| AmizinInjection | Amikacin | 250 mg/2 mL | Injection | 2ml x 1’s | 037609 | PKR 121.87 | PKR 60.94/mL | 🔒 Pharma Pro |
| Anacaine | Lidocaine | 1.0 % | Injection | 2ml x 50’s | 052412 | PKR 153.89 | PKR 1.54/mL | No comparator |
| Aprocor 12.5mg tabletRegistry verified | Aprocitentan | — | — | — | 133906Official source ↗ | No indexed price | — | — |
| Atrotil Diphenoxylate HCl | Atropine | 2.5 mg | Tablet | 50x10's | 032156 | PKR 439.68 | PKR 0.88/tablet | 🔒 Pharma Pro |
| Axo-C | Chloroquine | 250 mg | Tablet | 500's | 106265 | PKR 848.57 | PKR 1.70/tablet | 🔒 Pharma Pro |
| Axo-C | Chloroquine | 50 mg/5 mL | Syrup | 60ml | 106266 | PKR 26.38 | PKR 0.44/mL | 🔒 Pharma Pro |
| B-Quin | Moxifloxacin | 400 mg | Tablet | 1 x 5’s | 056275 | PKR 877.13 | PKR 175.43/tablet | 🔒 Pharma Pro |
| Bitether | Artemether | 80 mg/mL | Injection | 1ml x 6’s | 077818 | PKR 886.36 | PKR 147.73/mL | 🔒 Pharma Pro |
| Bitether | Artemether | 80 mg/mL | Injection | 1ml x 5’s | 077818 | PKR 738.63 | PKR 147.73/mL | 🔒 Pharma Pro |
| Cithrox | Ciprofloxacin | 250 mg | IV infusion | 1x10’s | 029429 | PKR 221.59 | PKR 22.16/vial/unit | 🔒 Pharma Pro |
| Cithrox | Ciprofloxacin | 500 mg | IV infusion | 1x10’s | 029430 | PKR 406.25 | PKR 40.63/vial/unit | 🔒 Pharma Pro |
| Cithrox | Ciprofloxacin | 200 mg/100 mL | IV infusion | 100ml | 031671 | PKR 332.39 | PKR 3.32/mL | 🔒 Pharma Pro |
| Cithrox 125mg/5ml SuspensionRegistry verified | Ciprofloxacin | — | — | — | 136897Official source ↗ | No indexed price | — | — |
| Cithrox 250mg/5ml SuspensionRegistry verified | Ciprofloxacin | — | — | — | 136898Official source ↗ | No indexed price | — | — |
| Cithrox-750 | Ciprofloxacin | 750 mg | Tablet | 1 x 10’s | 073227 | PKR 424.71 | PKR 42.47/tablet | 🔒 Pharma Pro |
| CLS 20mg TabletRegistry verified | Tadalafil | — | — | — | 133908Official source ↗ | No indexed price | — | — |
| CLS 5mg TabletRegistry verified | Tadalafil | — | — | — | 133907Official source ↗ | No indexed price | — | — |
| Colesa 4gm SachetRegistry verified | Anhydrous Cholestyramine | — | — | — | 136906Official source ↗ | No indexed price | — | — |
| Devidone | Risperidone | 1 mg | Tablet | 10'S | 081640 | PKR 221.59 | PKR 22.16/tablet | 🔒 Pharma Pro |
| Devidone | Risperidone | 2 mg | Tablet | 10'S | 081641 | PKR 360.08 | PKR 36.01/tablet | 🔒 Pharma Pro |
| Dubalac | Lactulose | 3.35 g/5 mL | Syrup | 120ml` | 040560 | PKR 273.29 | — | No comparator |
| Etroxin 90mg TabletRegistry verified | Etoricoxib | — | — | — | 135743Official source ↗ | No indexed price | — | — |
| Fordeme- 250Injection | Ceftazidime | 250 mg | Injection | Vial | 036592 | PKR 147.49 | PKR 147.49/vial/unit | 🔒 Pharma Pro |
| Fordeme–1000Injection | Ceftazidime | 1000 mg | Injection | Vial | 036594 | PKR 421.42 | PKR 421.42/vial/unit | 🔒 Pharma Pro |
| Fordeme–500Injection | Ceftazidime | 500 mg | Injection | Vial | 036593 | PKR 224.36 | PKR 224.36/vial/unit | 🔒 Pharma Pro |
| Fusemid | Furosemide | 20 mg/2 mL | Injection | 2ml x 50’s | 037607 | PKR 340.75 | PKR 3.41/mL | 🔒 Pharma Pro |
| Genzy | Gentamicin | 40 mg/2 mL | Injection | 2ml x 5’s | 037611 | PKR 110.80 | PKR 11.08/mL | 🔒 Pharma Pro |
| Genzy | Gentamicin | 80 mg/2 mL | Injection | 2ml x 5's | 037612 | PKR 147.73 | PKR 14.77/mL | 🔒 Pharma Pro |
| Gepep 40mg/5ml SuspensionRegistry verified | Famotidine | — | — | — | 136908Official source ↗ | No indexed price | — | — |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.